Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 6/20 | 0.46 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.45 |
| ▸ | F2 | P00734 | 6/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.39 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.39 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.39 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3374820 | 0.85 | PLA2G2A (0.54) | F2 | |
| SCHEMBL5187867 | 0.82 | MAPT (0.51) | F2GAA | |
| SCHEMBL17531344 | 0.79 | SERPINE1 (0.42) | ESR1SERPINE1GAAAKR1C4AKR1C3 | |
| SCHEMBL89250 | 0.78 | MAPT (0.53) | GAA | |
| SCHEMBL3490269 | 0.78 | MAPT (0.53) | GAA | |
| SCHEMBL5175776 | 0.77 | PLA2G2A (0.51) | F2 | |
| SCHEMBL18643853 | 0.75 | MAPT (0.59) | ESR1GAA | |
| SCHEMBL22667824 | 0.74 | CA12 (0.59) | ESR1SERPINE1AKR1C4AKR1C3AKR1C2 | |
| SCHEMBL3487346 | 0.74 | PLA2G2A (0.47) | F2GAA | |
| SCHEMBL5671326 | 0.74 | ESR1 (0.71) | ESR1AKR1C4AKR1C3AKR1C2AKR1C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1863477-B1 | 3,4-SUBSTITUTED PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF HYPERTENSION | NOVARTIS AG (CH) | 2010-11-03 | — | — | EP | disclosed |
| US-7807709-B2 | Organic compounds | NOVARTIS AG (CH) | 2010-10-05 | — | — | US | disclosed |
| US-20080194549-A1 | Organic Compounds | NOVARTIS AG (CH) | 2008-08-14 | — | — | US | disclosed |
| EP-1863477-A1 | 3,4-SUBSTITUTED PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF HYPERTENSION | Novartis AG (CH) | 2007-12-12 | — | — | EP | disclosed |
| WO-2006100036-A1 | 3, 4-SUBSTITUTED PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF HYPERTENSION | NOVARTIS AG (CH) | 2006-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194549-A1 | Organic Compounds | REN, ACE, OTC | ESR1 4129/4885SERPINE1 32/4885F2 82/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.